Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,025 JPY | +1.69% | -1.87% | -1.35% |
May. 29 | Asahi Kasei Offering to Buy Calliditas Therapeutics for SEK11.8 Billion | MT |
May. 28 | Health Care Stocks Post Broad Decline -- Health Care Roundup | DJ |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- With regards to fundamentals, the enterprise value to sales ratio is at 0.75 for the current period. Therefore, the company is undervalued.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company does not generate enough profits, which is an alarming weak point.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Diversified Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.35% | 9.04B | A- | ||
-1.05% | 74.34B | B | ||
-0.76% | 46.86B | A- | ||
+6.80% | 34.35B | C | ||
+9.37% | 18.1B | B | ||
+12.81% | 11.92B | A- | ||
-3.01% | 10.43B | - | ||
-20.72% | 10.33B | B | ||
-11.01% | 7.84B | C- | ||
-3.85% | 7.52B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 3407 Stock
- Ratings Asahi Kasei Corporation